Optogenetics' promise: Pacing and cardioversion by light?

Future Cardiology

Volumn 10, Issue 1, 2014, Pages 1-4

  Ambrosi, Christina M ^a   Entcheva, Emilia ^a  

^a St Francis Hospital The Heart Center   (United States)

Author keywords

arrhythmia; cardioversion; cell therapy; defibrillation; gene therapy; optogenetics; pacing

Indexed keywords

SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; BRAIN DEPTH STIMULATION; CARDIOVERSION; CELL FUNCTION; DEVICE THERAPY; ELECTRIC ACTIVITY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART PACING; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTED HEART PACEMAKER; OPTOGENETICS; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOMATIC GENE THERAPY; VIRAL GENE THERAPY;

ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; ELECTRIC COUNTERSHOCK; HUMANS; OPTOGENETICS;

EID: 84891057774     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.89     Document Type: Review

References (22)

1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: Calendar year 2009 -a world society of arrhythmia's project. Pacing Clin. Electrophysiol. 34(8), 1013-1027 (2011
2. Hauser RG, Hayes DL, Kallinen LM et al. Clinical experience with pacemaker pulse generators and transvenous leads: An 8 year prospective multicenter study. Heart Rhythm 4(2), 154-160 (2007
3. Baumert J, Schmitt C, Ladwig KH. Psychophysiologic and affective parameters associated with pain intensity of cardiac cardioverter defibrillator shock discharges. Psychosom. Med. 68(4), 591-597 (2006
4. Deisseroth K, Feng G, Majewska AK, Miesenbock G, Ting A, Schnitzer MJ. Next-generation optical technologies for illuminating genetically targeted brain circuits. J. Neurosci. 26(41), 10380-10386 (2006
5. Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron 71(1), 9-34 (2011
6. Entcheva E. Cardiac optogenetics. Am. J. Physiol. Heart Circ. Physiol. 304(9), H1179-H1191 (2013
7. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science 324(5925), 354-359 (2009
8. Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun. 4, 1376 (2013
9. Boyle PM, Williams JC, Ambrosi CM, Entcheva E, Trayanova NA. A comprehensive multiscale framework for simulating optogenetics in the heart. Nat. Commun. 4, 2370 (2013
10. Jia Z, Valiunas V, Lu Z et al. Stimulating cardiac muscle by light: Cardiac optogenetics by cell delivery. Circ. Arrhythm. Electrophysiol. 4(5), 753-760 (2011
11. Arrenberg AB, Stainier DY, Baier H, Huisken J. Optogenetic control of cardiac function. Science 330(6006), 971-974 (2010
12. Bruegmann T, Malan D, Hesse M et al. Optogenetic control of heart muscle in vitro and in vivo. Nat. Methods 7(11), 897-900 (2010
13. Abilez OJ, Wong J, Prakash R, Deisseroth K, Zarins CK, Kuhl E. Multiscale computational models for optogenetic control of cardiac function. Biophys. J. 101(6), 1326-1334 (2011
14. Williams JC, Xu J, Lu Z et al. Computational optogenetics: Empirically-derived voltage-and light-sensitive channelrhodopsin-2 model. PLoS Comput. Biol. 9(9), e1003220 (2013
15. Jessup M, Greenberg B, Mancini D et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A Phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ATPase in patients with advanced heart failure. Circulation 124(3), 304-313 (2011
16. Bolli R, Chugh AR, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised Phase 1 trial. Lancet 378(9806), 1847-1857 (2011
17. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised Phase 1 trial. Lancet 379(9819), 895-904 (2012
18. Ambrosi CM, Chen K, Kalra J et al. Distribution of donor cells alters energy requirements for optogenetic control of the heart. Heart Rhythm 10(5), S96 (2013
19. Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2(2), 334-371 (2010
20. Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: Immune challenges and strategies to circumvent them. Rev. Med. Virol. 23(6), 399-413 (2013
21. Lin JY, Knutsen PM, Muller A, Kleinfeld D, Tsien RY. ReaChR: A red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat. Neurosci. 16(10), 1499-1508 (2013
22. Kim TI, McCall JG, Jung YH et al. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science 340(6129), 211-216 (2013